Characteristic | Total (N = 115) | (%) | Neoadjuvant RCT (N = 23) | (%) | Other therapies (N = 92) | (%) |
---|---|---|---|---|---|---|
Sex | ||||||
Male | 62 | 53.9 | 13 | 56.5 | 49 | 53.3 |
Female | 53 | 46.1 | 10 | 43.5 | 43 | 46.7 |
Mean age, years (range) | 59.27 (20–95) | 52.7 (23–74) | 60.91 (20–95) | |||
Karnofsky Performance Status | ||||||
40 | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
50 | 0 | 0 | 0 | 0 | 0 | 0 |
60 | 4 | 3.5 | 0 | 0 | 4 | 4.3 |
70 | 4 | 3.5 | 0 | 0 | 4 | 4.3 |
80 | 36 | 31.3 | 5 | 21.7 | 31 | 33.7 |
90 | 56 | 48.7 | 13 | 56.5 | 43 | 46.7 |
100 | 13 | 11.3 | 5 | 21.7 | 8 | 8.7 |
n/a | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
Anatomic location | ||||||
Upper extremity | 10 | 8.7 | 0 | 0 | 10 | 10.9 |
Lower extremity | 66 | 57.4 | 18 | 78.3 | 48 | 52.2 |
Pelvis | 6 | 5.2 | 3 | 13 | 3 | 3.3 |
Head/neck | 6 | 5.2 | 0 | 0 | 6 | 6.5 |
Trunk wall | 15 | 13 | 1 | 4.3 | 14 | 15.2 |
Retroperitoneal | 8 | 7 | 1 | 4.3 | 7 | 7.6 |
Intra-abdominal | 4 | 3.5 | 0 | 0 | 4 | 4.3 |
Sarcoma Subtype | ||||||
Liposarcoma/Myxoid Liposarcoma | 25 | 21.7 | 1 | 4.3 | 24 | 26.1 |
Myxofibrosarcoma | 26 | 22.6 | 6 | 26.1 | 20 | 21.7 |
Undifferentiated pleomorphic sarcoma | 21 | 18.3 | 5 | 21.7 | 16 | 17.4 |
Synovial cell sarcoma | 12 | 10.4 | 5 | 21.7 | 7 | 7.6 |
Malignant peripheral nerve sheath tumor | 8 | 7 | 1 | 4.3 | 7 | 7.6 |
Leiomyosarcoma | 9 | 7.8 | 1 | 4.3 | 8 | 8.7 |
Angiosarcoma | 5 | 4.3 | 2 | 8.7 | 3 | 3.3 |
Spindle cell sarcoma | 3 | 2.6 | 0 | 0 | 3 | 3.3 |
Fibrosarcoma | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
Giant cell sarcoma | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
Small cell/Clear cell sarcoma | 2 | 1.7 | 1 | 4.3 | 1 | 1.1 |
Epitheloid sarcoma | 1 | 0.9 | 1 | 4.3 | 0 | 0 |
Myxoinflammatory fibroblastic sarcoma | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
Mean tumor size, cm (range) | 10.63 (1.5–41.6) | 10.35 (3.5–16) | 10.71 (1.5–41.6) | |||
Tumor depth | ||||||
Superficial | 14 | 12.2 | 2 | 8.7 | 12 | 13 |
Deep | 85 | 73.9 | 20 | 87 | 65 | 70.7 |
n/a | 16 | 13.9 | 1 | 4.3 | 14 | 15.2 |
Grade | ||||||
G2 | 53 | 46.1 | 8 | 34.8 | 45 | 48.9 |
G3 | 62 | 53.9 | 15 | 65.2 | 47 | 51.1 |
Resection margin | ||||||
R0 | 92 | 80 | 21 | 91.3 | 71 | 77.2 |
R1 | 10 | 8.7 | 1 | 4.3 | 9 | 9.8 |
R2 | 2 | 1.7 | 0 | 0 | 2 | 2.2 |
n/a | 11 | 9.6 | 1 | 4.3 | 10 | 10.9 |
Mean single radiation dose, Gy (range) | 2.1 (1.2–5.0) | 1.9 (1.6–2.15) | 2.13 (1.2–5.0) | |||
Mean total radiation dose, Gy (range) | 58.4 (25.0–75.7) | 54.1 (48.8–60.2) | 59.5 (25.0–75.7) | |||
Targeted therapy | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
Hyperthermia | 22 | 19.1 | 2 | 8.7 | 20 | 21.7 |
Local recurrence/progress | 27 | 23.5 | 2 | 8.7 | 25 | 27.2 |
Therapy local recurrence | ||||||
Resection | 20 | 17.4 | 2 | 8.7 | 18 | 19.6 |
Radiotherapy | 4 | 3.5 | 0 | 0 | 5 | 5.4 |
Chemotherapy | 11 | 9.6 | 0 | 0 | 11 | 12 |
Targeted Therapy | 2 | 1.7 | 0 | 0 | 2 | 2.2 |
Hyperthermia | 3 | 2.6 | 0 | 0 | 3 | 3.3 |
Distant metastases | 42 | 36.5 | 6 | 26.1 | 36 | 39.1 |
Lungs | 33 | 28.7 | 5 | 21.7 | 28 | 30.4 |
Bones | 3 | 2.6 | 0 | 0 | 3 | 3.3 |
Liver | 4 | 3.5 | 0 | 0 | 4 | 4.3 |
Lymph nodes | 2 | 1.7 | 1 | 4.3 | 1 | 1.1 |
Other | 7 | 6.1 | 0 | 0 | 7 | 7.6 |
Therapy distant metastases | ||||||
Resection | 20 | 17.4 | 5 | 21.7 | 15 | 16.3 |
Radiotherapy | 9 | 7.8 | 1 | 4.3 | 8 | 8.7 |
Chemotherapy | 16 | 13.9 | 1 | 4.3 | 15 | 16.3 |
Targeted Therapy | 1 | 0.9 | 0 | 0 | 1 | 1.1 |
Hyperthermia | 2 | 1.7 | 0 | 0 | 2 | 2.2 |
Death | 37 | 32.2 | 6 | 26.1 | 31 | 33.7 |